Grace Therapeutics Inc (GRCE) — Who's Buying and Selling (13F, Q2 2026)

GRCE ranks #7187 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

GRCE is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

34 institutions disclose a position in GRCE, but none treat it as a major bet — even Birchview Capital, LP, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Activest Wealth Management has trimmed its GRCE position for two straight quarters, cutting it by $258.0 while still holding $224.0.

GRCE is up 0.5% today, and institutions have been net buyers of $2.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

GRCE reported a net loss of $7.8M in its latest fiscal year.

• Not yet profitable — net loss of $7.8M in the latest fiscal year
• Net income improved year over year, from -$9.6M to -$7.8M
• Operating cash flow was negative, using $8.9M in cash
• Current ratio of 8.10x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.04x equity — within a conventional range